. . . . . . . . . . "approved"@en . . . . . . . "The mechanism of action of trimethobenzamide as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomiting center apparently are not similarly inhibited."@en . " "@en . . . . "For the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis."@en . . "The mean elimination half-life of trimethobenzamide is 7 to 9 hours."@en . . . . "Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate."@en . . . . . . . . . . . . . . . . . . . . . . . . . . . "Between 30 \u2013 50% of a single dose in humans is excreted unchanged in the urine within 48\u201372 hours."@en . "Oral LD₅₀ in mice is 1600 mg/kg."@en . "N-[[4-(2-Dimethylaminoethoxy)phenyl]methyl]-3,4,5-trimethoxybenzamide"@en . . . "Trimethobenzamide"@en . . . . "138-56-7"@en . . . . . . . " "@en . . . . . "Trimetobenzamida"@en . . . . . . . . . . . . . . . . . "Trimethobenzamidum"@en . . . . . . . " # Hurley JD, Eshelman FN: Trimethobenzamide HCl in the treatment of nausea and vomiting associated with antineoplastic chemotherapy. J Clin Pharmacol. 1980 May-Jun;20(5-6 Pt 1):352-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7400373 # Hurley JD, Eshelman FN: Trimethobenzamide HCl in the treatment of nausea and vomiting associated with antineoplastic chemotherapy. J Clin Pharmacol. 1980 May-Jun;20(5-6 Pt 1):352-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7400373 # Dundee JW, Halliday F, Nicholl RM, Moore J: Studies of drugs given before anaesthesia. X. Two non-phenothiazine anti-emetics--cyclizine and trimethobenzamide. Br J Anaesth. 1966 Jan;38(1):50-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/5908416"@en . . . . . . . "The relative bioavailability of the capsule formulation compared to the solution is 100%."@en . . . . "Humans and other mammals"@en . . . . . "Vittorio Rossetti, Alessandro Dondoni, Giancarlo Fantin, \"N-(4-Hydroxybenzyl)-3,4,5-trimethoxybenzamide and method for producing trimethobenzamide chlorohydrate.\" U.S. Patent US4507499, issued December, 1969."@en . . .